Pfizer Ltd (PFIZER) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Pfizer Ltd on NSE and BSE, with an AI summary of each filing.
Please find enclosed unaudited financial results for the quarter and half year ended September 30, 2026 along with the limited review report.
Outcome · 03 Nov 2026, 7:52 pm
Pfizer Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 7:44 pm
Pfizer Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Crore) ■ Revenue: 727 (+13.2% YoY | +11.3% QoQ) ■ EBITDA: 261 (+13.6% YoY | +5.5% QoQ) ■ EBITDA Margin (%): 35.9 (+14 bps YoY | -197 bps QoQ) ■ PAT: 313 (+65.7% YoY | +53.2% QoQ) ■ EPS (INR): 47.1 (+14.0% YoY | +5.4% QoQ)
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve This is to inform you that a meeting ....
Intimation · 03 Nov 2026, 5:30 am
Pfizer Limited Schedules Board Meeting on 3rd Nov'26 for Q2 Results Pfizer Limited has scheduled a Board of Directors meeting on 3rd Nov'26 to consider, approve, and take on record the unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in the company's shares remains closed and will reopen 48 hours after the public disclosure of the financial results.
Pfizer Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 3, 2026, inter alia, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
Intimation · 03 Nov 2026, 5:30 am
Intimation for order issued by the Deputy/Additional Commissioner of Income Tax Transfer Pricing.
Others (Uncategorized) · 29 Sept 2026, 6:49 pm
Pfizer Receives Income Tax Penalty Order of Rs 1.26 Crore Pfizer Limited received an order on 28th Sep'26 from the Deputy/Additional Commissioner of Income Tax Transfer Pricing, imposing a penalty of Rs. 1,26,34,050 under Section 271G of the Income Tax Act, 1961, for Assessment Year 2023-24. The penalty stems from the alleged non-furnishing of specific granular information during a transfer pricing audit. The company stated the order is not maintainable on merits, plans to file an appeal, and confirmed no material impact on its financial position or operational activities.
Intimation regarding change in Senior Management Personnel of the Company.
Change in Management · 18 Sept 2026, 9:56 pm
Pfizer India Senior Director Sharad Goswami Resigns Pfizer Limited announced that Sharad Goswami, Senior Director – Policy & Public Affairs, has resigned from the company to pursue external professional opportunities. He will formally step down from his role and cease to be part of the Senior Management Personnel effective from the close of business on 25th Sep'26.
Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
Outcome · 07 Sept 2026, 4:55 pm
Pfizer Discontinues Minipress XL; To Receive USD 13.9 Million Lump Sum Pfizer Limited announced the discontinuation of the marketing, distribution, and sale of Minipress XL effective 7th Sep'26, following a decision by Pfizer Inc. USA to cease manufacturing the product. In connection with this discontinuation, the company will receive a lump sum compensation payment of USD 13.9 Million (~Rs. 131.38 Crore) from Pfizer Inc. USA.
Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
Others (Uncategorized) · 07 Sept 2026, 4:54 pm
Pfizer Discontinues Minipress XL; Receives Rs. 131.38 Crore Lump Sum From Parent Pfizer Limited announced the immediate discontinuation of the marketing, distribution, and sale of Minipress XL effective 7th Sep'26, following a decision by parent entity Pfizer Inc. USA to stop manufacturing the drug. In connection with the discontinuation, the company will receive a one-time lump sum compensation of USD 13.9 million (~Rs. 131.38 Crore) from Pfizer Inc. USA.
Pursuant to Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we submit herewith the consolidated Scrutinizer''s Report of the votes cast through ....
Annual General Meeting · 30 Jul 2026, 12:50 am
Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, please find enclosed proceedings of the 75th Annual General Meeting of the Company held on July 28, 2026.
Annual General Meeting · 29 Jul 2026, 12:33 am
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....
Outcome · 28 Jul 2026, 7:22 pm
Pfizer Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Crore) ■ Revenue: 653 (+8.3% YoY | +3.8% QoQ) ■ EBITDA: 248 (+17.9% YoY | +4.9% QoQ) ■ EBITDA Margin (%): 37.9 (+308 bps YoY | +40 bps QoQ) ■ PAT: 204 (+6.6% YoY | +2.3% QoQ) ■ EPS (INR): 44.7 (+6.6% YoY | +5.9% QoQ)
Intimation of Resignation of Mr. Amit Agarwal, Executive Director -Finance & Chief Financial Officer
Change in Management · 27 Jul 2026, 10:02 pm
Pfizer CFO & Executive Director Amit Agarwal Resigns Pfizer Limited announced the resignation of Mr. Amit Agarwal, Executive Director – Finance & Chief Financial Officer, effective from the close of business on 8th Oct'26. Mr. Agarwal is leaving to pursue an opportunity outside the company. He will also cease to be a Director on the Board and a member of the Corporate Social Responsibility, Risk Management, and Board Administrative & Share Transfer Committees. The company disclosed the intimation on 27th Jul'26 as per SEBI regulations.
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....
Intimation · 28 Jul 2026, 5:30 am
Pfizer Board to Approve Q1FY27 Results on July 28, 2026 Pfizer Limited has scheduled a Board of Directors meeting on Tue, 28 Jul'26 to consider and approve its unaudited financial results for the quarter ending 30 Jun'26. Consequently, the trading window for dealing in the company's shares will remain closed from 30 Jun'26 until 48 hours after the financial results are publicly disclosed on 28 Jul'26.
Response to clarification sought with reference to news item appearing in ''The Hindu BusinessLine''
Others (Uncategorized) · 17 Jul 2026, 11:51 pm
Pfizer Confirms Premarin Cream Discontinuation; Impact Immaterial Pfizer Limited confirmed on 17 Jul'26 that it has temporarily discontinued its imported Premarin Vaginal Cream in India due to supply constraints. The company stated the product contributes less than 1% to total revenue and its discontinuation is not expected to have any material impact on financial performance, business operations, or profitability. Pfizer is actively exploring options to restore supply at the earliest. The event was not considered a material disclosure under SEBI LODR Regulations.
The Exchange has sought clarification from Pfizer Ltd on July 17, 2026, with reference to news appeared in https://www.thehindubusinessline.com/ dated July 17, 2026 quoting "Pfizer suspends ....
Others (Uncategorized) · 17 Jul 2026, 6:10 pm
Attached herewith is the letter sent to shareholders providing the weblink to access the Annual Report.
Annual Report · 07 Jul 2026, 10:32 pm
Notice of the 75th AGM of the Company scheduled to be held on July 28, 2026.
Annual General Meeting · 07 Jul 2026, 3:57 am
Annual Report for Financial Year ended 2025- 26
Others (Uncategorized) · 07 Jul 2026, 3:39 am
Please find enclosed Newspaper Advertisement for transfer of unclaimed Dividend and Shares to IEPF.
Dividend · 04 Jun 2026, 10:49 pm
Pfizer to Transfer Unclaimed Dividends and Shares to IEPF Pfizer Limited announced via a newspaper advertisement on 04 Jun'26 that it will transfer shares and dividends that have remained unclaimed for seven consecutive years to the Investor Education and Protection Fund (IEPF). This action is a standard corporate governance procedure affecting shareholders who have not claimed their dividends for this period. The company has published notices in the Business Standard (English) and Sakaal (Marathi) newspapers to inform the relevant shareholders of the impending transfer.
Special Window for Re-lodgement of Transfer and Dematerialisation of Physical Securities.
Others (Uncategorized) · 03 Jun 2026, 8:49 pm
Pfizer Announces Special Window for Dematerialisation of Physical Securities Pfizer Limited has informed exchanges about a newspaper advertisement published on 03 Jun'26. The announcement details a special window for shareholders to re-lodge requests for the transfer and dematerialisation of physical securities. This follows a Supreme Court judgement and provides a renewed opportunity for holders of physical shares to convert them into electronic form. The notice was published in the Business Standard (English) and Sakaal (Marathi) newspapers.
Appointment of Cost Auditors
Change in Management · 13 May 2026, 1:58 am
Pfizer Limited Appoints Cost Auditors for FY27 Pfizer Limited's Board of Directors appointed M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year ending 31 Mar'27. The appointment was made on 12 May'26, following the recommendation of the Audit Committee. The remuneration for the newly appointed firm is subject to shareholder ratification at the next Annual General Meeting. M/s. Kishore Bhatia & Associates is a Mumbai-based firm with experience in various sectors, including pharmaceuticals. No relationship with the Directors was disclosed.
The Board of Directors at their meeting held today approved convening of 75th Annual General Meeting of the Company on July 28, 2026.
Annual General Meeting · 13 May 2026, 1:47 am
Pfizer Limited Announces Date for its 75th Annual General Meeting Pfizer Limited announced that its Board of Directors, in a meeting on 12 May'26, approved the date for its 75th Annual General Meeting (AGM). The AGM is scheduled to be held on Tuesday, 28 Jul'26. The meeting will be conducted virtually through video-conferencing (VC) or other audio-visual means (OAVM), in compliance with regulatory circulars.
The Company has fixed Friday July 17, 2026 as the record date for determining entitlement of Members to the final dividend for the financial year ended March 31, 2026.
Dividend · 13 May 2026, 1:38 am
Pfizer Board Recommends Rs. 75/Share Dividend, Fixes Record Date Pfizer Limited's board, at its meeting on 12 May'26, recommended a final dividend of Rs. 75 per equity share (750%) for the financial year ended 31 Mar'26. The company has fixed 17 Jul'26 as the record date for determining shareholder entitlement to this dividend.
The Board of Directors has recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026.
Dividend · 13 May 2026, 1:36 am
Pfizer India Declares Rs. 75 Final Dividend; Sets Record Date Pfizer Limited's Board of Directors has recommended a final dividend of Rs. 75 per equity share (750% on face value of Rs. 10) for the financial year ended Mar 31, '26. The company announced this at its board meeting on May 12, '26. The Record Date for determining shareholder eligibility for this final dividend has been fixed as Friday, Jul 17, '26. This action is subject to shareholder approval.